These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hyperhomocysteinemia, C677T MTHFR polymorphism and ischemic stroke in Tunisian patients.
    Author: Salem-Berrabah OB, Mrissa R, Machghoul S, Hamida AB, N'siri B, Mazigh C, Aouni Z, Louati I, Layouni S, El Oudi M, Fekih-Mrissa N, Gritli N.
    Journal: Tunis Med; 2010 Sep; 88(9):655-9. PubMed ID: 20812180.
    Abstract:
    BACKGROUND: Hyperhomocysteinaemia has been identified as a strong risk factor for ischemic stroke (IS). A point mutation in methylene tetrahydrofolate reductase (MTHFR C677T) has been associated with increased plasma homocysteine (Hcy) levels. AIM: This preliminary study aimed to investigate whether hyperhomocysteinaemia and/or MTHFR C677T mutation are associated with ischemic stroke. METHODS: A case-control study including 50 consecutive patients with confirmed IS and 97 controls was performed. Fasting plasma homocysteine levels, MTHFR C677T genotypes were assessed. Other factors such as hypertension, obesity, dyslipidemia, diabetes mellitus, recurrent stroke tobacco and alcohol were investigated. RESULTS: Mean plasma homocysteine levels were significantly higher in IS patients than in controls (15.83+/-10.60) μmol/L vs 13.78+/-6.29 μmol/L, p=0.04), while no association of MTHFR C677T variant was observed even with homocysteine. The risk to develop ischemic stroke in hyperhomocysteinemic subjects was 2.4 times more than in subjects with normal Hcy levels (OR= 2.4; 95% CI: 1.13-5.06; p<0.05). CONCLUSION: Our findings suggest that high levels of homocysteine but not MTHFR C677T polymorphism represent risk factors for arterial ischemic stroke in Tunisian subjects.
    [Abstract] [Full Text] [Related] [New Search]